{
    "clinical_study": {
        "@rank": "18324", 
        "arm_group": [
            {
                "arm_group_label": "Niaspan", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will be randomized to Niaspan 1.5 g/d in addition to usual care statin lipid lowering agents.  The dose of Niaspan will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks.  The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patients will be randomized to placebo 1.5 g/d in addition to usual care statin lipid lowering agents.  The dose of placebo will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks.  The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl."
            }
        ], 
        "brief_summary": {
            "textblock": "The combination of HDL-C elevation, lowering of triglcerides and further LDL-C reduction\n      accomplished by the addition of niacin to statin medication would improve endothelial\n      function as compared to LDL-C reduction alone in patients with and without coronary artery\n      disease and the combination of low HDL-C/high triglycerides.\n\n      The combination of lipid lowering therapy would have beneficial effects on markers of\n      inflammation.  These benefits would be particularly evident in women."
        }, 
        "brief_title": "Benefit of Elevation of HDL-C in Women", 
        "completion_date": {
            "#text": "June 2005", 
            "@type": "Actual"
        }, 
        "condition": "Cardiovascular Outcomes", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Stable CAD patients on statin therapy with LDL-C between 90-135mg/dl and\n             triglycerides > 150mg/dl\n\n          -  Well-controlled diabetes with HbA1C < 7.5 currently on statin therapy, able to\n             tolerate Niacin without unstable blood glucose levels with LDL-C between 90-135mg/dl\n             and triglycerides > 150mg/dl\n\n          -  Stable patients on statin therapy with LDL-C between 90-135mg/dl and triglycerides >\n             150mg/dl\n\n        Exclusion Criteria:\n\n          -  History of MI, PTCA or surgery within previous 3 months\n\n          -  Currently on Niaspan and unwilling to withdraw Niaspan therapy or known intolerance\n             to niacin\n\n          -  Active or known gall bladder disease\n\n          -  Pregnant or nursing women\n\n          -  Significant comorbidity that precludes participation\n\n          -  Significant liver disease, active alcoholism, or LFT >1.5x's ULN at screening\n\n          -  Diabetes with Hg A1C < 7.5\n\n          -  PI perceived inability to comply with protocol"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921010", 
            "org_study_id": "3954"
        }, 
        "intervention": [
            {
                "arm_group_label": "Niaspan", 
                "description": "See Arm Description", 
                "intervention_name": "NIaspan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "See Arm Description", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Niacin", 
                "Nicotinic Acids"
            ]
        }, 
        "lastchanged_date": "August 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90048"
                }, 
                "name": "Cedars-Sinai Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Cedars-Sinai Medical Center", 
            "last_name": "C. Noel Bairey Merz, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "endothelial function", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921010"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cedars-Sinai Medical Center", 
            "investigator_full_name": "Noel Bairey Merz", 
            "investigator_title": "Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Cedars-Sinai Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cedars-Sinai Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2003", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}